-$0.52 Earnings Per Share Expected for TG Therapeutics Inc common stock (TGTX) This Quarter

Share on StockTwits

Wall Street brokerages forecast that TG Therapeutics Inc common stock (NASDAQ:TGTX) will post ($0.52) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for TG Therapeutics Inc common stock’s earnings. The lowest EPS estimate is ($0.55) and the highest is ($0.50). TG Therapeutics Inc common stock reported earnings per share of ($0.48) in the same quarter last year, which indicates a negative year-over-year growth rate of 8.3%. The business is scheduled to announce its next quarterly earnings report on Wednesday, November 14th.

On average, analysts expect that TG Therapeutics Inc common stock will report full year earnings of ($2.08) per share for the current year, with EPS estimates ranging from ($2.27) to ($1.80). For the next financial year, analysts anticipate that the business will post earnings of ($1.90) per share, with EPS estimates ranging from ($2.36) to ($0.73). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover TG Therapeutics Inc common stock.

TG Therapeutics Inc common stock (NASDAQ:TGTX) last released its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics Inc common stock had a negative net margin of 97,412.51% and a negative return on equity of 191.66%.

TGTX has been the topic of several recent analyst reports. BidaskClub cut shares of TG Therapeutics Inc common stock from a “hold” rating to a “sell” rating in a research report on Saturday, May 5th. Zacks Investment Research upgraded shares of TG Therapeutics Inc common stock from a “sell” rating to a “hold” rating in a research report on Thursday, July 26th. HC Wainwright reiterated a “buy” rating and set a $38.00 price objective on shares of TG Therapeutics Inc common stock in a research report on Tuesday, August 7th. ValuEngine cut shares of TG Therapeutics Inc common stock from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 16th. Finally, Raymond James reiterated a “buy” rating on shares of TG Therapeutics Inc common stock in a research report on Thursday, April 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. TG Therapeutics Inc common stock presently has a consensus rating of “Buy” and an average target price of $31.00.

In related news, CFO Sean A. Power sold 47,191 shares of the business’s stock in a transaction on Tuesday, July 3rd. The shares were sold at an average price of $13.21, for a total value of $623,393.11. Following the sale, the chief financial officer now owns 473,267 shares in the company, valued at $6,251,857.07. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William James Kennedy sold 25,071 shares of the business’s stock in a transaction on Thursday, June 14th. The stock was sold at an average price of $13.45, for a total transaction of $337,204.95. The disclosure for this sale can be found here. Insiders own 15.10% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. venBio Select Advisor LLC increased its position in TG Therapeutics Inc common stock by 58.7% in the first quarter. venBio Select Advisor LLC now owns 5,229,619 shares of the biopharmaceutical company’s stock worth $74,261,000 after purchasing an additional 1,935,156 shares during the last quarter. BlackRock Inc. increased its position in TG Therapeutics Inc common stock by 17.4% in the second quarter. BlackRock Inc. now owns 4,081,050 shares of the biopharmaceutical company’s stock worth $53,667,000 after purchasing an additional 605,844 shares during the last quarter. Wells Fargo & Company MN increased its position in TG Therapeutics Inc common stock by 2,148.1% in the second quarter. Wells Fargo & Company MN now owns 888,768 shares of the biopharmaceutical company’s stock worth $11,686,000 after purchasing an additional 849,233 shares during the last quarter. Columbus Circle Investors increased its position in TG Therapeutics Inc common stock by 39.6% in the first quarter. Columbus Circle Investors now owns 761,030 shares of the biopharmaceutical company’s stock worth $10,807,000 after purchasing an additional 215,976 shares during the last quarter. Finally, Northern Trust Corp increased its position in TG Therapeutics Inc common stock by 2.0% in the first quarter. Northern Trust Corp now owns 630,301 shares of the biopharmaceutical company’s stock worth $8,951,000 after purchasing an additional 12,517 shares during the last quarter. Institutional investors own 49.24% of the company’s stock.

TG Therapeutics Inc common stock opened at $11.85 on Monday, Marketbeat.com reports. The company has a market cap of $924.42 million, a PE ratio of -6.20 and a beta of 1.16. TG Therapeutics Inc common stock has a 1 year low of $7.25 and a 1 year high of $17.35.

About TG Therapeutics Inc common stock

TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.

Recommended Story: Growth Stocks, What They Are, What They Are Not

Get a free copy of the Zacks research report on TG Therapeutics Inc common stock (TGTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TG Therapeutics Inc common stock (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc common stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc common stock and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply